JP2021529531A5 - - Google Patents
Info
- Publication number
- JP2021529531A5 JP2021529531A5 JP2020573299A JP2020573299A JP2021529531A5 JP 2021529531 A5 JP2021529531 A5 JP 2021529531A5 JP 2020573299 A JP2020573299 A JP 2020573299A JP 2020573299 A JP2020573299 A JP 2020573299A JP 2021529531 A5 JP2021529531 A5 JP 2021529531A5
- Authority
- JP
- Japan
- Prior art keywords
- administration
- antibody
- recombinant
- herpesvirus
- genome
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024055149A JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
| JP2025156650A JP2025186440A (ja) | 2018-06-29 | 2025-09-22 | 抗体送達のための組成物及び方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692514P | 2018-06-29 | 2018-06-29 | |
| US62/692,514 | 2018-06-29 | ||
| US201862713066P | 2018-08-01 | 2018-08-01 | |
| US62/713,066 | 2018-08-01 | ||
| PCT/US2019/039939 WO2020006486A1 (en) | 2018-06-29 | 2019-06-28 | Compositions and methods for antibody delivery |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024055149A Division JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021529531A JP2021529531A (ja) | 2021-11-04 |
| JP2021529531A5 true JP2021529531A5 (enExample) | 2022-06-30 |
Family
ID=68985203
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020573299A Pending JP2021529531A (ja) | 2018-06-29 | 2019-06-28 | 抗体送達のための組成物及び方法 |
| JP2024055149A Active JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
| JP2025156650A Pending JP2025186440A (ja) | 2018-06-29 | 2025-09-22 | 抗体送達のための組成物及び方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024055149A Active JP7749055B2 (ja) | 2018-06-29 | 2024-03-29 | 抗体送達のための組成物及び方法 |
| JP2025156650A Pending JP2025186440A (ja) | 2018-06-29 | 2025-09-22 | 抗体送達のための組成物及び方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20210261649A1 (enExample) |
| EP (1) | EP3866924A4 (enExample) |
| JP (3) | JP2021529531A (enExample) |
| AU (2) | AU2019292580B2 (enExample) |
| CA (1) | CA3103374A1 (enExample) |
| WO (1) | WO2020006486A1 (enExample) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT3199552T (pt) | 2012-11-20 | 2020-03-25 | Sanofi Sa | Anticorpos anti-ceacam5 e suas utilizações |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| ES2796488T3 (es) | 2016-04-08 | 2020-11-27 | Krystal Biotech Inc | Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| MX2020011257A (es) | 2018-04-27 | 2021-01-15 | Krystal Biotech Inc | Ácidos nucleicos recombinantes que codifican una o más proteínas cosméticas para usos estéticos. |
| CN113454105A (zh) | 2019-02-08 | 2021-09-28 | 克里斯托生物技术股份有限公司 | 用于递送cftr多肽的组合物和方法 |
| JP7137696B2 (ja) | 2019-05-14 | 2022-09-14 | プロヴェンション・バイオ・インコーポレイテッド | １型糖尿病を予防するための方法および組成物 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| KR20230092863A (ko) | 2020-06-11 | 2023-06-26 | 프로벤션 바이오, 인코포레이티드 | 제1형 당뇨병을 예방하기 위한 방법 및 조성물 |
| IL301202A (en) | 2020-09-10 | 2023-05-01 | Vascular Biogenics Ltd | Antibodies against MOTILE SPERM DOMAIN CONTAINING PROTEIN 2 and methods of using them |
| CA3195512A1 (en) | 2020-10-14 | 2022-04-21 | Vahe Bedian | Compositions and methods for treatment of thyroid eye disease |
| JP7849358B2 (ja) | 2020-11-10 | 2026-04-21 | サノフイ | Ｃｅａｃａｍ５抗体－薬物コンジュゲート製剤 |
| IL303350A (en) | 2020-12-04 | 2023-08-01 | Macrogenics Inc | Preparations containing an antibody against HER2/NEU and their use |
| IL307350A (en) | 2021-04-02 | 2023-11-01 | Krystal Biotech Inc | Viral vectors for cancer treatment |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| CA3217029A1 (en) | 2021-05-30 | 2022-12-08 | Biolojic Design Ltd. | Engineered dual binding antibodies and uses thereof |
| WO2023274342A1 (zh) * | 2021-06-30 | 2023-01-05 | 江苏恒瑞医药股份有限公司 | 特异性结合baff和il-12/23的抗原结合分子及用途 |
| JP2024531151A (ja) | 2021-08-10 | 2024-08-29 | ビリジアン セラピューティクス， インコーポレイテッド | 甲状腺眼疾患の処置のための組成物、用量および方法 |
| CN118715242A (zh) * | 2021-10-05 | 2024-09-27 | 得克萨斯州大学系统董事会 | 包含b7-h3结合多肽的组合物和方法 |
| JP7767613B2 (ja) | 2021-11-15 | 2025-11-11 | システィミューン，インコーポレイテッド | 二重特異性抗体－カンプトテシン薬物複合体及びその製薬的使用 |
| US20250304680A1 (en) * | 2022-05-17 | 2025-10-02 | The Uab Research Foundation | Methods and compositions for treating or preventing inflammatory skin disorders |
| KR20250025381A (ko) | 2022-06-17 | 2025-02-21 | 아포지 바이오로직스, 인크. | 인터류킨 13에 결합하는 항체 및 사용 방법 |
| EP4547846A4 (en) * | 2022-06-30 | 2026-06-17 | Lonza Sales Ag | EDITABLE CELL LINES |
| WO2024182737A1 (en) * | 2023-03-01 | 2024-09-06 | The Brigham And Women’S Hospital, Inc. | Oncolytic viruses to treat brain cancer |
| CN116790615B (zh) * | 2023-07-11 | 2024-11-22 | 康霖生物科技（杭州）有限公司 | 一种用于过敏性疾病的基因治疗载体核酸构建体及其使用方法 |
| WO2026132377A1 (en) * | 2024-12-20 | 2026-06-25 | Universidad De Navarra | Replication-competent oncolytic virus comprising a sequence encoding an antibody or antibody fragment |
| WO2026153510A1 (zh) * | 2025-01-17 | 2026-07-23 | 苏州康宁杰瑞生物科技有限公司 | 针对激活素受体ii的抗体及其用途 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6610287B1 (en) * | 1990-04-16 | 2003-08-26 | The General Hospital Corporation | Transfer and expression of gene sequences into nervous system cells using herpes simplex virus mutants with deletions in genes for viral replication |
| US5658724A (en) * | 1992-07-31 | 1997-08-19 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus strains deficient for the essential immediate early genes ICP4 and ICP27 and methods for their production, growth and use |
| US6261552B1 (en) * | 1997-05-22 | 2001-07-17 | University Of Pittsburgh Of The Commonwealth System Of Higher Education | Herpes simplex virus vectors |
| GB0203285D0 (en) * | 2002-02-12 | 2002-03-27 | Brown Susanne M | An herpes simplex virus complex |
| MX361174B (es) * | 2003-12-23 | 2018-11-29 | Genentech Inc | Anticuerpos anti-il13 novedosos y sus usos. |
| AU2006304387A1 (en) * | 2005-10-14 | 2007-04-26 | Medimmune, Llc | Cell display of antibody libraries |
| WO2008121324A2 (en) * | 2007-03-30 | 2008-10-09 | Abbott Laboratories | Recombinant expression vector elements (reves) for enhancing expression of recombinant proteins in host cells |
| NO2700405T3 (enExample) * | 2008-05-29 | 2018-09-01 | ||
| CA2985649A1 (en) * | 2015-05-13 | 2016-11-17 | Sanofi Pasteur Biologics, Llc | Icp0-mediated enhanced expression system |
| US11155622B2 (en) * | 2015-12-17 | 2021-10-26 | Psioxus Therapeutics Limited | Virus encoding an anti-TCR-complex antibody or fragment |
| EP3400291B2 (en) * | 2016-01-08 | 2024-02-28 | Replimune Limited | Engineered virus |
| ES2796488T3 (es) * | 2016-04-08 | 2020-11-27 | Krystal Biotech Inc | Composiciones para el uso en métodos para el tratamiento de heridas, trastornos y enfermedades de la piel |
-
2019
- 2019-06-28 WO PCT/US2019/039939 patent/WO2020006486A1/en not_active Ceased
- 2019-06-28 JP JP2020573299A patent/JP2021529531A/ja active Pending
- 2019-06-28 US US17/255,383 patent/US20210261649A1/en active Pending
- 2019-06-28 CA CA3103374A patent/CA3103374A1/en active Pending
- 2019-06-28 AU AU2019292580A patent/AU2019292580B2/en active Active
- 2019-06-28 EP EP19826446.7A patent/EP3866924A4/en active Pending
-
2024
- 2024-03-29 JP JP2024055149A patent/JP7749055B2/ja active Active
-
2025
- 2025-09-22 JP JP2025156650A patent/JP2025186440A/ja active Pending
-
2026
- 2026-05-08 AU AU2026203527A patent/AU2026203527A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11993663B2 (en) | Low-viscosity antigen binding proteins and methods of making them | |
| AU2019292580B2 (en) | Compositions and methods for antibody delivery | |
| JP6879921B2 (ja) | システインプロテアーゼ | |
| JP6961486B2 (ja) | システインプロテアーゼ | |
| AU2011219715B2 (en) | Stable antibody containing compositions | |
| CN114671952A (zh) | 具有改善的结合、功能和安全性特征的抗cd154抗体及其在人免疫治疗中的用途 | |
| US20250230186A1 (en) | Stabilised Protein Solutions | |
| JP2024532726A5 (enExample) | ||
| AU2019257683A1 (en) | Treatment of atopic dermatitis | |
| JP2023535842A5 (enExample) | ||
| EP3958903A1 (en) | Antibody formulation | |
| US10745463B2 (en) | Hyper-glycosylated antibodies with selective Fc receptor binding | |
| CA3175685A1 (en) | Auto-injector assembly | |
| WO2020176730A1 (en) | Antibody formulation | |
| EA043899B1 (ru) | Антигенсвязывающие белки, характеризующиеся низкой вязкостью, и способы их получения | |
| HK1240619A1 (en) | Cysteine protease |